Prescribing for comorbid disease in a palliative population: Focus on the use of lipid-lowering medications

Internal Medicine Journal

Volumn 44, Issue 2, 2014, Pages 177-184

  Russell, B J ^a   Rowett, D ^b   Abernethy, A P ^c,d,e   Currow, D C ^e  

^a ST VINCENT S HOSPITAL   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

Comorbidity; Lipid regulating agent; Palliative care; Physician prescribing pattern; Polypharmacy; Prevention

Indexed keywords

ANTILIPEMIC AGENT;

AGED; AUSTRALIA; CARDIOVASCULAR DISEASES; CLINICAL PRACTICE; COMORBIDITY; FEMALE; HUMAN; INAPPROPRIATE PRESCRIBING; MALE; NEEDS ASSESSMENT; ORGANIZATION AND MANAGEMENT; PALLIATIVE THERAPY; PREVENTION AND CONTROL; PREVENTIVE HEALTH SERVICE; PROCEDURES; PROSPECTIVE STUDY; RISK ASSESSMENT; STANDARDS; STATISTICS AND NUMERICAL DATA; TERMINALLY ILL PATIENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AUSTRALIA; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INAPPROPRIATE PRESCRIBING; MALE; NEEDS ASSESSMENT; PALLIATIVE CARE; PHYSICIAN'S PRACTICE PATTERNS; PREVENTIVE HEALTH SERVICES; PROSPECTIVE STUDIES; RISK ASSESSMENT; TERMINALLY ILL;

EID: 84894095383     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12340     Document Type: Article

References (30)

1. Stevenson J, Abernethy AP, Miller C, Currow DC. Managing comorbidities in patients at the end of life. BMJ 2004; 329: 909-912.
2. Maddison AR, Fisher J, Johnston G. Preventive medication use among persons with limited life expectancy. Prog Palliat Care 2011; 19: 15-21.
3. Raijmakers NJ, van Zuylen L, Furst CJ, Beccaro M, Maiorana L, Pilastri P etal. Variation in medication use in cancer patients at the end of life: a cross-sectional analysis. Support Care Cancer 2013; 21: 1003-1011.
4. Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer 2009; 17: 745-748.
5. Fede A, Miranda M, Antonangelo D, Trevizan L, Schaffhausser H, Hamermesz B etal. Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer 2011; 19: 1313-1318.
6. Currow DC, Stevenson JP, Abernethy AP, Plummer J, Shelby-James TM. Prescribing in palliative care as death approaches. J Am Geriatr Soc 2007; 55: 590-595.
7. Britt H, Miller GC, Charles J, Henderson J, Bayram C, Pan Y etal. General Practice Activity in Australia 2008-09. Sydney: Australian Institute of Health and Welfare and University of Sydney; 2009.
8. Mant A, Lowinger J, Hall W, Whicker S, Ringland C, Stark H. Statins down under. Br J Clin Pharmacol 2007; 63: 125-127.
9. Vollrath AM, Sinclair C, Hallenbeck J. Discontinuing cardiovascular medications at the end of life: lipid-lowering agents. J Palliat Med 2005; 8: 876-881.
10. Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000; 132: 780-787.
11. Silveira MJ, Kazanis AS, Shevrin MP. Statins in the last six months of life: a recognizable, life-limiting condition does not decrease their use. J Palliat Med 2008; 11: 685-693.
12. Tanvetyanon T, Choudhury AM. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliat Care 2006; 22: 281-285.
13. Bayliss EA, Bronsert MR, Reifler LM, Ellis JL, Steiner JF, McQuillen DB etal. Statin prescribing patterns in a cohort of cancer patients with poor prognosis. J Palliat Med 2013; 16: 412-418.
14. Johnson CE, Girgis A, Paul CL, Currow DC. Cancer specialists' palliative care referral practices and perceptions: results of a national survey. Palliat Med 2008; 22: 51-57.
15. Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC. The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice. BMC Palliat Care 2005; 4: 7.
16. Eagar K, Green J, Gordon R. An Australian casemix classification for palliative care: technical development and results. Palliat Med 2004; 18: 217-226.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
18. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335: 806-808.
19. Bird S, Allingham SF, Masso MR, Banfield M. PCOC National Report on patient outcomes in palliative care in Australia January-June 2012. 2012.
20. Riechelmann RP, Krzyzanowska MK, O'Carroll A, Zimmermann C. Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer 2007; 15: 1407-1412.
21. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996; 14: 447-450.
22. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997; 315: 1096-1099.
23. Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004; 351: 2870-2874.
24. Vollrath AM, Sinclair C, Hallenbeck J. Lipid-lowering agents: the authors' response. J Palliat Med 2006; 9: 621-622.
25. Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ 2000; 320: 469-472.
26. Clayton JM, Hancock K, Parker S, Butow PN, Walder S, Carrick S etal. Sustaining hope when communicating with terminally ill patients and their families: a systematic review. Psychooncology 2008; 17: 641-659.
27. Currow DC, Wheeler JL, Glare PA, Kaasa S, Abernethy AP. A framework for generalizability in palliative care. J Pain Symptom Manage 2009; 37: 373-386.
28. Currow DC, Abernethy AP. Frameworks for approaching prescribing at the end of life. Arch Intern Med 2006; 166: 2404.
29. Currow DC, To TH, Abernethy AP. Prescribing at times of clinical transition in chronic or progressive diseases. Int J Gerontol 2009; 3: 1-8.
30. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006; 166: 605-609.